Last Updated : May 6, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Imcivree | setmelanotide | Bardet-Biedl syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cabometyx | cabozantinib | Advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Atriance | nelarabine | T-cell acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | ||
| Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cablivi | caplacizumab | Acquired thrombotic thrombocytopenic purpura (aTTP) | Do not reimburse | Complete | ||
| Opdualag | nivolumab and relatlimab | unresectable or metastatic melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Active | ||
| Lumakras | sotorasib | KRAS G12C-mutated advanced NSCLC | Do not reimburse | Active | ||
| Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Reimburse with clinical criteria and/or conditions | Active |
Last Updated : May 6, 2024